Search Results 761-770 of 18345 for alopecia

1. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

   ... alopecia (Grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for > 6 months] ...

2. A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib - Mayo Clinic

   ... alopecia and Grade 2, prior platinum-therapy related neuropathy. As judged by the investigator, active gastrointestinal disease or other condition that will ...

3. MEDI5395 Advanced Solid Tumors - Clinical Trials

   Participation eligibility · Vitiligo or alopecia; · Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; · Any chronic skin condition ...

4. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

   Participation eligibility · Patients with vitiligo or alopecia; · Patients with hypothyroidism (e.g., following Hashimoto syndrome), stable on hormone replacement ...

5. A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer - Mayo Clinic

   0 grade 1 (except for alopecia or neurotoxicity grade ≤ 2). Known human immunodeficiency virus (HIV) infection. Known history of active viral hepatitis ...

6. Acamprosate (oral route) - Side effects & dosage - Mayo Clinic

   It is not a cure for alcoholism, but rather will help you maintain abstinence. This medicine is available only with your doctor's prescription. This product is ...

7. Study of DF9001 in Patients With Advanced Solid Tumors - Mayo Clinic

   0; however, alopecia ≤Grade 2, endocrinopathies ≤Grade 2, and sensory neuropathy ≤Grade 2 is acceptable. 12. Participants who have received an anti-PD-(L ...

8. Facial fillers for wrinkles - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

9. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... alopecia. Patients with clinical signs of central nervous system (CNS) involvement of MM. Patients with known or suspected light chain amyloidosis of any ...

10. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

    03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not ...